 |
|
|
| |
Efficacy and viral resistance are comparable when maraviroc is administered once daily or twice daily with boosted protease inhibitors in treatment-experienced patients
|
| |
| |
Reported by Jules Levin EACS 2011 Oct 12-15 Belgrade Serbia
Carlo-Federico Perno,1 Charles Craig,2 Steve Taylor,3 José Arribas,4 Robert Burnside,5 David Hardy,6 Hans-Jürgen Stellbrink,7 David A Cooper,8
Jean-Michel Molina,9 Elna van der Ryst,2 Mike Westby,2 Hernan Valdez,10 Jayvant Heera5
1University of Rome, Tor Vergata, Italy; 2Pfizer Global R&D, Sandwich, UK; 3Birmingham Heartlands Hospital, Birmingham, UK; 4Hospital La Paz, Madrid, Spain; 5Pfizer Inc., Groton, CT, USA;
6Cedars-Sinai Medical Center/Geffen School of Medicine-UCLA, Los Angeles, CA, USA; 7ICH Study Center, Hamburg, Germany; 8Kirby Institute, University of New South Wales,
Sydney, Australia; 9Assistance Publique-Hopitaux de Paris, Paris, France; 10Pfizer Inc., New York, NY, USA
References
1. Fatkenheuer G, et al. Nat Med 2005; 11: 1170-1172.
2. Gulick RM, et al. N Engl J Med 2008; 359: 1429-1441.
3. Weatherley B et al. Poster 17a presented at the 9th International Workshop
on Clinical Pharmacology of HIV Therapy, New Orleans, LA, 7-9 April, 2008.
4. Schapiro JM, et al. Antivir Ther 2011; 16: 395-404.
|
| |
|
|
|
|
|
